Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 29 results found since Jan 2013.
Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
CONCLUSIONS: The growth of tumor tissue in osteosarcoma bearing rats is inhibited in Ad-VEGF-siRNA group, Ad-VEGF-siRNA + neoadjuvant chemotherapy group and Ad-VEGF-siRNA + anti-angiogenesis chemotherapy group. The effect in Ad-VEGF-siRNA + neoadjuvant chemotherapy is more significant than simple biological therapy or Ad-VEGF-siRNA + anti-angiogenesis chemotherapy.
PMID: 26636524 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - December 6, 2015 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells
Conclusion: Survivin siRNA combined with the neoadjuvant chemotherapy can significantly enhance the sensitivity of MCF-7 cells to chemotherapeutics and cell apoptosis. This technology has important potential value in the therapeutic study of breast cancer.
Source: Journal of Cancer Research and Therapeutics - February 15, 2016 Category: Cancer & Oncology Authors: Honglin DongLuyu YaoWeilin BiFusheng WangWei SongYonggang Lv Source Type: research
SiRNA targeting PFK1 inhibits proliferation and migration and enhances radiosensitivity by suppressing glycolysis in colorectal cancer.
CONCLUSIONS: Our study indicates that high expression of PFK1 is negatively correlated with radiosensitivity in CRC and likely accelerates the proliferation and migration of CRC cells. Downregulation of PFK1 may enhance the radiosensitivity of CRC cells in vivo and in vitro by inhibiting glycolysis.
PMID: 33042398 [PubMed]
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research
Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to cisplatin‑induced apoptosis.
Abstract
Although surgical excision following neoadjuvant chemotherapy has contributed to the long-term survival of osteosarcoma patients, patients that do not respond to commonly used drugs including cisplatin, have a poor prognosis. Autophagy is important in the inhibition of chemotherapeutic apoptosis. Therefore, we investigated whether knockdown of Beclin1-associated autophagy-related key regulator (Barkor/ATG14) promoted cisplatin-induced apoptosis in a drug-resistant osteosarcoma cell line in vitro. Saos-2 cells were transfected with Barkor siRNA. Sensitivity of the Barkor siRNA-transfected cell line to ci...
Source: International Journal of Molecular Medicine - December 9, 2013 Category: Molecular Biology Authors: Zhao Z, Tao L, Shen C, Liu B, Yang Z, Tao H Tags: Int J Mol Med Source Type: research
A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
This study investigated the therapeutic potential of targeting the BAG-1 protein co-chaperone in trastuzumab-responsive or -resistant cells. In the METABRIC dataset, BAG-1 mRNA was significantly elevated in HER2+ breast tumors and predicted overall survival in a multivariate analysis (HR = 0.81; p = 0.022). In a breast cell line panel, BAG-1 protein was increased in HER2+ cells and was required for optimal growth as shown by siRNA knockdown. Overexpression of BAG-1S in HER2+ SKBR3 cells blocked growth inhibition by trastuzumab, whereas overexpression of a mutant BAG-1S protein (BAG-1S H3AB), defective in binding HSC70, pot...
Source: Oncotarget - March 10, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients
Abstract
Multidrug resistance (MDR) is one of the most important factors leading to chemotherapeutic failure in patients with breast cancer. The invasive/metastatic ability of MDR cells is strengthened compared with their parental cells. However, the mechanisms underlying MDR have not been fully elucidated. We found that CD44 and the cellular prion protein (PrPc) were both overexpressed in MDR cells (MCF7/Adr and H69AR). Subsequently, we chose the human breast cancer cell line MCF7/Adr, which is resistant to adriamycin, for further research. We discovered that PrPc physically and functionally interacted with CD44. The knoc...
Source: Molecular Carcinogenesis - May 16, 2013 Category: Molecular Biology Authors: Yuanyuan Cheng, Lili Tao, Jiawen Xu, Qingquan Li, Juan Yu, Yiting Jin, Qi Chen, Zude Xu, Qiang Zou, Xiuping Liu Tags: Research Article Source Type: research
GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer
In this report, we investigated the role of glutathione peroxidase 2 (GPX2) in CRPC. GPX2 expression was analyzed in rat and human CRPC cells. Next, we determined the proliferation rate and level of reactive oxygen species (ROS) in GPX2-small interfering RNA (siRNA)-transfected CRPC cells. For in vivo analysis, siRNA-transfected cells were subcutaneously implanted into normal and castrated nude mice. Further, immunohistochemical and prognostic analyses of GPX2 were performed using human specimens. Silencing of GPX2 caused significant growth inhibition and increased intracellular ROS in both rat (PCai1) and human (PC3) CRPC...
Source: Carcinogenesis - August 27, 2014 Category: Cancer & Oncology Authors: Naiki, T., Naiki-Ito, A., Asamoto, M., Kawai, N., Tozawa, K., Etani, T., Sato, S., Suzuki, S., Shirai, T., Kohri, K., Takahashi, S. Tags: Original Manuscript Source Type: research
Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC)
Conclusion: We suggest SFRP1 as a novel predictive marker of chemotherapy sensitivity to taxane, anthracycline and platinum-containing chemotherapy independent of Ki67 expression. Further on, we have shown the influence of SFRP1 on cancerous characteristics thus, suggesting SFRP1 as potential prognostic marker. Molecular role of SFRP1 may be the influence on enrichment of cancer stem cell population which are known to be resistant against chemotherapeutics and radiation and are usually slow proliferating. Interestingly, the mTOR/PI3K signaling might be activated via loss of SFRP1 which could display an opportunity for pati...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Huelsewig, C., Bernemann, C., Ruckert, C., Kiesel, L., Goette, M., Rody, A., Pusztai, L., Hempel, G., Liedtke, C. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway.
In conclusion, IFNβ leads to apoptosis in NPC cells in an autocrine way via the induction of TRAIL expression and subsequent activation of the TRAIL-signaling pathway. The mechanism described could at least partly explain the clinical benefit of IFNβ in the treatment of NPC. Further studies in a mouse-xenograft model are warranted to substantiate this effect in vivo.
PMID: 29581840 [PubMed]
Source: Oncotarget - March 29, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
CONCLUSION: Our study suggested that Nek2B can bind to β-catenin and the co-expression correlated with TNBC patients poor prognosis. It appears that Nek2B and β-catenin might synergize to promote chemotherapy resistance.
PMID: 31174562 [PubMed - in process]
Source: Clinical Genitourinary Cancer - June 6, 2019 Category: Cancer & Oncology Authors: Shen H, Yan W, Yuan J, Wang Z, Wang C Tags: J Exp Clin Cancer Res Source Type: research
NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch
Antioxidants (Basel). 2021 Aug 28;10(9):1380. doi: 10.3390/antiox10091380.ABSTRACTRadiation resistance is a significant clinical problem in rectal cancer treatment, the mechanisms of which are poorly understood. NRF2 signalling is known to contribute to chemo/radioresistance in some cancers, but its role in therapeutic resistance in colorectal cancer (CRC) is unexplored. Using siRNA and CRiSPR/Cas9 isogenic CRC cell lines, we investigated the effect of the knockdown and upregulation of the NRF2 pathway on chemo-radiosensitivity. Poly (A) enriched RNA sequencing and geneset enrichment analysis (GSEA) were carried out on bot...
Source: Cell Research - September 28, 2021 Category: Cytology Authors: S éan M O'Cathail Chieh-Hsi Wu Rachael Thomas Maria A Hawkins Tim S Maughan Annabelle Lewis Source Type: research
Cancers, Vol. 14, Pages 3726: Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
In conclusion, a compound screen together with a functional genomic approach identified Src as a potential chemosensitising target in OAC, which could be assessed in a clinical study for poor prognosis OAC patients.
Source: Cancers - July 30, 2022 Category: Cancer & Oncology Authors: Niamh H. McCabe Leanne Stevenson Enya Scanlon Rosalie Douglas Susanna Kennedy Oliver Keminer Bj örn Windshügel Daniela Zisterer Richard D. Kennedy Jaine K. Blayney Richard C. Turkington Tags: Article Source Type: research
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers
Abstract: Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 w...
Source: Molecular Oncology - January 13, 2014 Category: Cancer & Oncology Authors: Balázs Győrffy, Giulia Bottai, Jacqueline Lehmann-Che, György Kéri, László Őrfi, Takayuki Iwamoto, Christine Desmedt, Giampaolo Bianchini, Nicholas C. Turner, Hugues de Thè, Fabrice André, Christos Sotiriou, Gabriel N. Hortobagyi, Angelo Di Leo, Tags: Research articles Source Type: research
Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling
Conclusion:
We could firstly show that SFRP1 strongly correlates with the triple negative breast cancer subtype and secondly, that SFRP1 might be used as a marker stratifying patients to positively respond to neoadjuvant chemotherapy. The mechanisms by which tumor suppressor SFRP1 influences carcinogenic properties of cancer cells do not rely on Wnt signaling, thereby demonstrating the complexity of tumor associated signaling pathways.
Source: Molecular Cancer - July 17, 2014 Category: Cancer & Oncology Authors: Christof BernemannCarolin HülsewigChristian RuckertSarah SchäferLena BlümelGeorg HempelMartin GötteBurkhard GrevePeter BarthLudwig KieselCornelia Liedtke Source Type: research
Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance
Conclusion: Acquired L/LT resistance in the two BT474 R lines is due to selection of HER2 L755S subclones present in parental cells. The higher HER2 L755S levels in BT474 parentals compared with other parentals, and detection of its subclonal presence in a pre-treatment HER2+ BC patient, suggest that sensitive mutation detection methods will be needed to identify patients with potentially actionable HER family mutations in primary tumor. Treating this patient group with an irreversible TKI like Afa may prevent resistance and improve clinical outcome of this subset of HER2+ BC.Citation Format: Xiaowei Xu, Agostina Nardone, ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Xu, X., Nardone, A., Hu, H., Qin, L., Nanda, S., Heiser, L., Wang, N., Covington, K., Chen, E., Renwick, A., Mitchell, T., Shea, M., Wang, T., De Angelis, C., Contreras, A., Gutierrez, C., Fuqua, S., Chamness, G., Shaw, C., Li, M., Wheeler, D., Hilsenbeck Tags: Experimental and Molecular Therapeutics Source Type: research
